BioNTech stops making cell therapy at Maryland site after dropping germ cell tumor indication
BioNTech said it’s stopping work on an experimental cell therapy in certain indications, and is winding down cell therapy manufacturing at its Gaithersburg, MD site …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.